Stock Taper
SCREENER COMPARE ANY 2 STOCKS
UNCY
UNICYCIVE THERAPEUTICS, INC.
NASDAQ
$5.26
▼ DOWN 4.27% (-0.23)

KEY STATISTICS

Market Cap$140.58 M
52w High$8.74
52w Low$3.71
Dividend Yield—
Frequency—
P/E-2.97
Volume608.23K
Shares Out.26.70M

COMPANY

LEADERSHIP

Shalabh K. Gupta
CHIEF EXECUTIVE
Shalabh K. Gupta

COMPENSATION 2026

Salary$572,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$2,391,621

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 12, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
21

PRICE TARGET

Target High$22.00
Target Low$22.00
Target Median$22.00
Target Consensus$22.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$902.78K
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2025-06-20Reverse1:10

PRICE

$5.26 ▼ DOWN 4.27% (−$0.23)
OVERLAYS
$5.33$5.40$5.489:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.26

About Unicycive Therapeutics, Inc.

https://www.unicycive.com ↗

Unicycive Therapeutics, Inc., a California-based biotech founded in 2016, develops novel kidney disease therapies, including Renazorb for hyperphosphatemia and UNI 494 for acute kidney injury.

INDUSTRY

Biotechnology

A PRODUCT UNICYCIVE THERAPEUTICS, INC. IS KNOWN FOR

Oxylanthanum Carbonate (OLC)
Oxylanthanum Carbonate (OLC)

Oxylanthanum Carbonate (OLC) is Unicycive Therapeutics' investigational oral phosphate binder for CKD patients on dialysis, with an NDA resubmitted to the FDA aiming for approval by June 29, 2026.

COMPETITORS

COMPETITOR
AKBA COMPARE
ARDX COMPARE
FMS COMPARE
SNY COMPARE
TAK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
52
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 805.7K
IWM
0.00% · 608.2K
DFAS
0.00% · 67.8K
R2SC.L
0.01% · 66.8K
GSSC
0.01% · 27.2K
XRS2.DE
0.00% · 22.4K
RSSL
0.00% · 11.6K
URTY
0.00% · 994
RESM
0.00% · 49
RTYS.L
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
30.99%
HOLDERS
51
TOP 12 OF 51 · RANKED BY POSITION SIZE
Vivo Capital, LLC
1.8M sh · $11.78M
Millennium Management LLC
1.4M sh · $9.21M
Octagon Capital Advisors LP
1.0M sh · $5.77M
Nantahala Capital Management, LLC
939.2K sh · $5.42M
Great Point Partners LLC
796.6K sh · $5.24M
Vanguard Group Inc
788.6K sh · $4.55M
Logos Global Management LP
473.6K sh · $3.12M
Citadel Advisors LLC
258.3K sh · $1.49M
Integral Health Asset Management, LLC
225.0K sh · $1.48M
Geode Capital Management, LLC
203.7K sh · $1.34M
Cantor Fitzgerald, L. P.
200.0K sh · $1.15M
Susquehanna International Group, Llp
199.2K sh · $1.31M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kenkare-Mitra Sara
Purchase · 47.9K shares
2026-05-14
★
DIRECTOR
Laumas Sandeep
Purchase · 47.9K shares
2026-05-14
★
DIRECTOR, OFFICER: CEO
Gupta Shalabh K.
Purchase · 762.2K shares
2026-05-14
★
DIRECTOR
Kenkare-Mitra Sara
Purchase · 42.1K shares
2026-05-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
SPECULATIVE BUY 1
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Benchmark SPECULATIVE BUY B. Riley Securities BUY Guggenheim BUY Noble Capital Markets OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
RLMD$4.33COMPARE
IMUX$15.40COMPARE
CBUS$1.65COMPARE
BMEA$1.73COMPARE
VXRT$0.50COMPARE
ACRV$2.06COMPARE
CAMP$4.15COMPARE
HYFT$1.39COMPARE